Loading...
Market
Will Lilly announce another strategic agreement with a biotech company by end of 2024?
5
Resolution / Starting Odds
Yes • 50%
No • 50%
Official press releases from Eli Lilly
Story
Radionetics Oncology Enters $140M Strategic Agreement With Lilly, Acquisition Option for $1B
Jul 1, 2024, 02:51 PM
Radionetics Oncology has entered into a strategic agreement with Eli Lilly and Company. As part of the deal, Radionetics will receive a $140 million upfront payment. In return, Lilly gains the exclusive right to acquire Radionetics for $1 billion. The agreement focuses on enhancing Lilly's cancer drug pipeline with radiopharmaceuticals developed by Radionetics. Lilly inks the deal with the biotech startup to expand its radiopharmaceutical offerings.
View original story
Similar markets
Yes • 50%
No • 50%
Biotech company • 25%
Pharmaceutical company • 25%
Medical device company • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
